Stem Cell Laboratory, Department of Biomedical Sciences, State University of Novi Pazar, Novi Pazar, Serbia
Recent studies have identified several tissues as a new source of mesenchymal stem cells (MSCs) for therapy. The purpose of many studies were to investigate the therapy with MSCs in a model of healed myocardial infarction (MI). Transcatheter cell injection may require multi-imaging modalities to optimize delivery. Some studies sought to evaluate whether endomyocardial transplantation (EMT) of MSCs could be guided by real-time 3D echocardiography (RT3DE) in treating chronic, postinfarction left ventricular (LV) dysfunction in animals.
In several studies, EMT of MSCs in patients with anterior MI did not result in increase in ejection fraction (EF). Slight improvement of myocardial perfusion was noticed in the MSCs group. This finding may indicate better microcirculation enhanced by MSCs, but small number of patients allow for hypothesis rather than final statement.
The LV function did not improve, but the long-term LV volumes in the high-dosage group were reduced. During the follow-up, there were also no additional arrhythmogenic incidences.
However, due to the small patient number, the clinical impact is limited.
The beneficial effect of autologous MSCs in post-MI patients with depressed LV function may be mediated by restoration of autonomic control, and improved exercise tolerance.